Sarepta Therapeutics Inc

Sarepta's stock rallied 13% despite a five-month delay in its Elevidys safety study, as investors weigh the new trial site against weak sales and high short interest.

Capricor Therapeutics shares plummeted 67% after FDA staff flagged concerns about deramiocel's efficacy data, wiping out $766 million in market value ahead of a key advisory committee vote.

Arrowhead Pharmaceuticals shares experienced heightened trading activity and a slight decline following its transition to the S&P MidCap 400 index. Goldman Sachs reiterated a Neutral stance, highlighting pivotal 2026 clinical data and competitive pressures.